ID   U-CH17S
AC   CVCL_VR45
DR   ATCC; CRL-3401
DR   GEO; GSM2585627
DR   GEO; GSM2585628
DR   GEO; GSM2585629
DR   Wikidata; Q98133717
RX   PubMed=29148152;
WW   Info; Chordoma Foundation; -; https://www.chordomafoundation.org/researchers/disease-models/u-ch17s/
CC   Doubling time: 3-17 days (PubMed=29148152); 5-7 days (Chordoma Foundation); ~8-10 days (ATCC=CRL-3401).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous or homozygous (PubMed=29148152).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ATCC=CRL-3401; PubMed=29148152
ST   Amelogenin: X,Y
ST   CSF1PO: 12,14
ST   D13S317: 11
ST   D16S539: 9,13 (PubMed=29148152)
ST   D16S539: 13 (ATCC=CRL-3401)
ST   D18S51: 12,15
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 9.2,12
ST   Penta D: 12
ST   Penta E: 11,14
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VR43 ! U-CH17M
OI   CVCL_VR44 ! U-CH17P
OI   CVCL_B6R8 ! U-CH17PII
SX   Male
AG   38Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 10-04-25; Version: 12
//
RX   PubMed=29148152; DOI=10.1002/ijc.31161;
RA   Jager D., Lechel A., Tharehalli U., Seeling C., Moller P.,
RA   Barth T.F.E., Mellert K.;
RT   "U-CH17P, -M and -S, a new cell culture system for tumor diversity and
RT   progression in chordoma.";
RL   Int. J. Cancer 142:1369-1378(2018).
//